SYNACT PHARMA ApS: Financial statements 2017
CVR: 34459975
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -9,991,876 and a net result of DKK -8,278,722 compared with DKK -8,884,785 the year before. Equity in the 2017 report amounted to DKK 1,646,605. The solvency ratio was 16.3%.
- Gross Profit
- DKK -9,991,876
- Profit/Loss
- DKK -8,278,722
- Equity
- DKK 1,646,605
- Total Assets
- DKK 10,091,051
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -10 mio. | -8.3 mio. | 1.6 mio. | - |
| 2016 | - | -9.9 mio. | -8.9 mio. | 9.9 mio. | - |
| 2015 | - | -309 t. | -783 t. | -3.9 mio. | - |
| 2014 | - | -343 t. | -768 t. | -3.1 mio. | - |
| 2013 | - | -953 t. | -1.1 mio. | -2.3 mio. | - |
Keep an eye on SYNACT PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
SYNACT PHARMA ApS has published its annual report for 2016. Gross profit came to DKK -9,884,650, and the net result was DKK -8,884,785.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity in the 2025 report amounted to DKK 20,295,649.